Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : Expects 'Gradual' Uptake for Alzheimer's Drug Aduhelm, May Review Price

06/23/2021 | 03:27pm EDT


ę MT Newswires 2021
All news about BIOGEN INC.
08:38aBIOGEN : Canaccord Genuity Adjusts Biogen's Price Target to $423 From $359, Reit..
MT
07/26BIOGEN : Ionis Report 'Positive' Alzheimer's Treatment Data From Phase 1b Trial
MT
07/26BIOGEN : and Ionis report positive topline clinical data on investigational Alzh..
PU
07/26Biogen Inc. and Ionis Pharmaceuticals, Inc. Announces Positive Topline Clinic..
CI
07/26BIOGEN : and Eisai Announce ADUHELM™á(aducanumab-avwa) Data Presentations ..
AQ
07/26BIOGEN : Reduction in Biomarkers of Alzheimer's Disease Pathophysiology Followin..
PU
07/26BIOGEN : Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE,..
PU
07/26BIOGEN : Considerations for the Real-World Management of ARIA from the Aducanuma..
PU
07/26BIOGEN : Item-level Analysis of Clinical Measures in Patients with Early Symptom..
PU
07/26BIOGEN : Results of the First-in-Human, Randomized, Double-Blind, Placebo-Contro..
PU
More news
Financials (USD)
Sales 2021 10 766 M - -
Net income 2021 2 067 M - -
Net Debt 2021 1 321 M - -
P/E ratio 2021 24,1x
Yield 2021 -
Capitalization 49 469 M 49 469 M -
EV / Sales 2021 4,72x
EV / Sales 2022 4,32x
Nbr of Employees 9 100
Free-Float 84,9%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 331,93 $
Average target price 416,78 $
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors